Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tralokinumab

tralokinumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tralokinumab

14 trials tracked of tralokinumab: 10 in phase 3 or 4 and 8 with published results. The most-cited published study has 227 citations.

14Trials tracked
10Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 3 10 Phase 2 4
  1. Phase 3 A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma Completed · 227 cited
  2. Phase 3 Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). Completed · 134 cited
  3. Phase 3 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) Completed · 53 cited
  4. Phase 3 Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 Completed · 49 cited
  5. Phase 3 Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND Completed · 49 cited
  6. Phase 3 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) Completed · 29 cited
Show 8 more trials
  1. Phase 3 Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma Completed · 23 cited
  2. Phase 3 Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) Completed · 1 cited
  3. Phase 3 Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 Completed
  4. Phase 3 Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis Completed
  5. Phase 2 Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) Completed
  6. Phase 2 Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids Completed
  7. Phase 2 A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Completed
  8. Phase 2 Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy
Neurology Meta-analysis
Network meta-analysis of pediatric atopic dermatitis treatments shows dupilumab and pimecrolimus efficacy Dupilumab and Pimecrolimus Lead New Rankings for Children's Eczema Relief
This network meta-analysis evaluated dupilumab, pimecrolimus, melatonin, probiotics, tralokinumab, nemolizumab, and vitamin D for pediatric …
A new analysis ranks the top treatments for children's eczema, with dupilumab and pimecrolimus leading for symptom relief.
Frontiers May 2, 2026
Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks
Dermatology RCT
Tralokinumab maintains efficacy in adults with moderate-to-severe atopic dermatitis up to 152 weeks Tralokinumab keeps skin clear for up to four years in adults
This post hoc interim analysis of the ECZTEND open-label extension trial evaluated adults with moderate-to-severe atopic dermatitis who comp…
New data shows a specific eczema drug keeps skin clear for up to four years in adults who need long-term relief.
May 1, 2026